Neurocrine Biosciences, Inc.
General ticker "NBIX" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $14.4B (TTM average)
Neurocrine Biosciences, Inc. follows the US Stock Market performance with the rate: 40.5%.
Estimated limits based on current volatility of 1.7%: low 133.49$, high 138.10$
Factors to consider:
- Earnings expected soon, date: 2026-10-27 amc
- Total employees count: 2000 (+11.1%) as of 2025
- Top business risk factors: Regulatory and compliance, Commercialization challenges, Market competition, Intellectual property risks, Economic downturns and volatility
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [141.92$, 200.50$]
- 2026-12-31 to 2027-12-31 estimated range: [153.70$, 215.48$]
Financial Metrics affecting the NBIX estimates:
- Negative: with PPE of 28.6 at the end of fiscal year the price was high
- Positive: 15.80 < Operating profit margin, % of 21.64
- Positive: 69.38 < Shareholder equity ratio, % of 70.24 <= 81.92
- Positive: -2.60 < Investing cash flow per share per price, % of -1.84
- Positive: 4.90 < Operating cash flow per share per price, % of 5.43
- Positive: Industry inventory ratio change (median), % of -0.31 <= 0
- Positive: -6.44 < Industry operating cash flow per share per price (median), % of -1.98
- Positive: -51.61 < Industry operating profit margin (median), % of -17.91
Short-term NBIX quotes
Long-term NBIX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1,887.10MM | $2,355.30MM | $2,860.50MM |
| Operating Expenses | $1,636.20MM | $1,784.80MM | $2,241.40MM |
| Operating Income | $250.90MM | $570.50MM | $619.10MM |
| Non-Operating Income | $81.20MM | $-84.50MM | $86.30MM |
| R&D Expense | $565.00MM | $731.10MM | $1,015.70MM |
| Income(Loss) | $332.10MM | $486.00MM | $705.40MM |
| Taxes | $82.40MM | $144.70MM | $226.80MM |
| Net Income(Loss)* | $249.70MM | $341.30MM | $478.60MM |
| Stockholders Equity | $2,232.00MM | $2,589.70MM | $3,253.10MM |
| Inventory | $38.30MM | $57.40MM | $69.00MM |
| Assets | $3,251.40MM | $3,718.70MM | $4,631.50MM |
| Operating Cash Flow | $389.90MM | $595.40MM | $782.70MM |
| Capital expenditure | $28.30MM | $38.20MM | $34.00MM |
| Investing Cash Flow | $-467.10MM | $-126.80MM | $-264.40MM |
| Financing Cash Flow | $65.30MM | $-486.70MM | $-38.30MM |
| Earnings Per Share** | $2.56 | $3.40 | $4.81 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.